The Benefits and Risks of Medical AI Chatbots

By Michael Awood

September 7, 2023

Large Language Models (LLMs) are gaining prevalence in healthcare. OpenAI, in collaboration with Microsoft Research, is exploring the use cases of such technology in healthcare and medical applications. They aim to understand the opportunities, limitations, and risks in this context. Google’s Language Model for Dialog Application or “LaMDA” (replaced by their Pre-training with Abstracted Langage Modeling “PaLM”) and OpenAI’s previous Generative Pretrained Transformer 3.5 (GPT-3.5) have also been under study for medical applications. Interestingly, these LLMs, although not specifically trained for healthcare, demonstrated competence in the medical field using open-source internet information.

These LLMs have been used to develop the next tool in a physician’s pocket – a medical AI chatbot. By integrating OpenAI’s GPT-4 with medical expertise, a chatbot that engages users conversationally was created. Users initiate a session by entering a query or “prompt” in natural language, and GPT-4 responds, creating a human-like conversation. The system’s ability to maintain the context of an ongoing conversation enhances its usability and natural feel.

However, its responses are sensitive to the prompt’s wording, necessitating careful development and testing of prompts. GPT-4 can accurately answer definitive prompts, but it can also engage in complex interactions with prompts that lack a single correct answer. It provides error checking, identifying mistakes in its work and human-generated content.

GPT-4’s medical knowledge can serve tasks such as consultation, diagnosis, and education. It can read medical research material and engage in an informed discussion about it. However, like human reasoning, GPT-4 is fallible. It makes mistakes, but it can also identify them. The medical AI chatbot can write medical notes based on exchanges between providers and patients, even making sense of the subjective, objective, assessment, and plan (SOAP) format. It also includes billing codes as necessary. The chatbot can understand authorisation information, and prescriptions, that comply with Health Level Seven (HL7) and Fast Healthcare Interoperability Resources (FHIR) standards.

However, problems such as false responses or “hallucinations” pose dangers in a medical context. For instance, the AI chatbot created a medical note recording a body-mass index (BMI) without any related detail entered into the system. In another instance, the chatbot indicated no problems for the patient, but the clinician identified signs of medical complications.

While these tools can significantly enhance the consultation process and assist both the provider and patient, they are not without flaws and risks. The article speaks to a solution where the chatbot re-reads its information and it correctly identified these errors.

The article also highlights other improvements needed in the LLMs and chatbots. This is just the beginning of new possibilities and new risks. But, there is no denying that these tools hold the potential to optimise healthcare services.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.